ArticleAvicenna journal of phytomedicine2026
Evaluation of anti-gonadal activity of chloroform fraction of
Article in Avicenna journal of phytomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Anti-gonadal activity of chloroform fraction of Materials and Methods: The Ch-TPHmL (5 mg/100 g of body-weight (BW)/day) and standard antiandrogenic agent cyproterone acetate (CyPA) at the dose of 2.5 mg/100 g of BW were given to male rats for 28 days. Sperm profile, serum gonadotrophins and testosterone were measured. Testicular superoxide-dismutase, catalase activities and zygomorphic-expression, malondialdehyde, conjugated-diene, TNF-α levels and immunohistochemical markers were evaluated. Testicular steroidogenic enzyme activities and androgen receptor (AR), StAR, HSD, Bcl2, P53, caspase-3 and BAX gene expressions were observed. LC-MS study was done for Ch-TPHmL. Results: Sperm profile, gonadotrophins, testosterone as well as testicular steroidogenic key enzyme activities were reduced significantly (p<0.05) and StAR, AR, HSD genes expressions were downregulated in Ch-TPHmLE and CyPA treated groups compared to the control group. Testicular anti-oxidant enzyme activities and zygomorphic-expression patterns were reduced significantly and malondialdehyde, conjugated-diene, TNF-α were increased significantly in the Ch-TPHmLE and CyPA treated groups. Testicular caspase-3 gene and proapoptotic genes P53, and BAX expressions were upregulated but anti-apoptotic gene Bcl2 was downregulated as confirmed by elevated number of apoptotic germ cells in immunostaining. The bio-active phyto-compounds γ-Sistosterol, Stigmasterol, Dehydroergosterol, β-Amyrin, Lupenol, and α-Amyrone were identified by LC-MS analysis of Ch-TPHmLE. Conclusion: It is concluded that the synergistic action of these phyto-molecule(s) of chloroform fraction of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.